Table I.
Demographics, research involvement and endorsement of buprenorphine and CBTa treatment.
|
M (SD) |
||||
|---|---|---|---|---|
| Total sample n = 571 | Buprenorphine | CBT | Research involvement n = 120 | |
| Age (years) (M, SD) | 51 (11) | – | – | 51 (11) |
| Gender (n, %) | ||||
| Female | 345 (61) | 3.26 (0.78) | 2.42 (1.13) | 60 (51) |
| Male | 221 (39) | 3.43 (0.85) | 2.63 (1.18)** | 57 (49) |
| Race/ethnicity (n, %) | ||||
| White | 384 (70) | 3.36 (0.85) | 2.54 (1.15) | 74 (64) |
| African–American | 90 (16) | 3.18 (0.73) | 2.27 (0.99) | 22 (19) |
| Hispanic/Latinos | 39 (7) | 3.48 (0.81) | 2.67 (1.28) | 9 (8) |
| Native-American | 19 (4) | 3.31 (0.76) | 2.39 (1.13) | 6 (5) |
| Asian/P. Islander | 17 (3) | 3.29 (0.75) | 2.64 (1.38) | 5 (4) |
| Provider type (n, %) | ||||
| Medical staff | 143 (25) | 3.55 (0.90)*** | 2.42 (1.07) | 37 (31) |
| Social workers | 172 (30) | 3.21 (0.77)*** | 2.61 (1.17) | 32 (27) |
| Psychologists | 132 (23) | 3.34 (0.74)*** | 2.48 (1.16) | 27 (23) |
| Counsellors | 124 (22) | 3.16 (0.77)*** | 2.47 (1.22) | 24 (20) |
Notes:
a
Endorsement measured on a five-point Likert-type scale (range = 1–5), higher scores indicate stronger endorsement.
**
p < 0.01
***
p < 0.001.